National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer

Launched by NATIONAL CANCER INSTITUTE (NCI) · Oct 29, 2019

Keywords

ClinConnect Summary

This clinical trial is focused on understanding liver cancer better, specifically two types: hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). Researchers are looking for ways to improve treatments for these cancers, which are becoming more common and serious. If you are 18 years or older and have liver cancer, and have received or plan to receive immune therapy, you might be eligible to participate in this study.

As a participant, you will visit the NIH Clinical Center, where your medical history will be reviewed, and various tests will be conducted. This includes checking your medical records, collecting samples like blood and urine, and possibly looking at tissue samples from previous procedures. You'll also learn about any genetic mutations that may be linked to your cancer and what treatment options are available. While there are no specific follow-up visits required just for this study, you will be contacted every six months to check on your health. Participants may be involved in the study for life, helping researchers find better ways to fight liver cancer.

Gender

ALL

Eligibility criteria

• * INCLUSION CRITERIA:
• • Patients with histologically/ultrasound/imaging confirmed or suspicious lesions of HCC or CCA.
• • Patients with planned or a history of at least 1 dose of immunotherapy for HCC or CCA.
• • Ability of subject to understand and the willingness to sign a written informed consent document.
• • Age greater than or equal to 18 years old at date of study consent.
• EXCLUSION CRITERIA:
• • - Patients with known HIV infection (as these patients may have abnormal test results which may confound the endpoints of this study)